346.36MMarket Cap-3243P/E (TTM)
6.410High6.010Low65.16KVolume6.200Open6.200Pre Close404.22KTurnover0.23%Turnover RatioLossP/E (Static)55.33MShares8.44052wk High-24.17P/B180.27MFloat Cap2.70052wk Low--Dividend TTM28.80MShs Float28.265Historical High--Div YieldTTM6.45%Amplitude2.700Historical Low6.203Avg Price1Lot Size
Foghorn Therapeutics Stock Forum
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet